- Lonza has signed a global exclusive licensing agreement with China Medical System Holdings (CMS) for its NeuroPortal transferrin receptor 1 (TfR1) blood-brain barrier technology, covering up to two products targeting neurodegenerative diseases.
- The agreement includes an upfront payment, development and commercial milestones, and royalties on net sales for Lonza. CMS will receive exclusive rights to the technology for the agreed product targets.
Lonza has signed a global exclusive licensing agreement with China Medical System Holdings Limited (CMS) for its NeuroPortal transferrin receptor 1 (TfR1) blood-brain barrier (BBB) technology. The agreement covers the use of the platform in up to two products targeting neurodegenerative diseases. CMS, a pharmaceutical company headquartered in Hong Kong, focuses on developing and commercializing specialty medicines, including treatments for central nervous system (CNS) disorders.
The NeuroPortal technology is designed to help therapeutic molecules cross the blood-brain barrier, which limits the delivery of many medicines to the brain. It offers binding variants with different affinities, allowing developers to evaluate receptor engagement, transport across the barrier and brain exposure. According to Lonza, preclinical studies showed that the technology outperformed an industry benchmark when used as an immunoglobulin G (IgG) fusion and when combined with its GlycoConnect platform.
Under the agreement, CMS has secured exclusive rights to the technology for the agreed product targets. Lonza will receive an upfront payment, development and commercial milestone payments, and royalties on net sales. The company will continue to offer licensing rights to NeuroPortal TfR1 for other therapeutic programs.
The platform can be used with genetic fusion or bioconjugation approaches. Lonza also offers expertise in protein expression, bioconjugation and developability to support the evaluation of CNS drug delivery strategies. The company plans to present detailed results from its NeuroPortal TfR1 platform at the 18th annual Protein and Antibody Engineering Summit (PEGS) in Lisbon, Portugal, from November 16–19.